A number of other research analysts also recently issued reports on the stock. FinnCap reaffirmed a buy rating and issued a GBX 100 ($1.38) price objective on shares of Motif Bio in a research report on Wednesday, November 22nd. Northland Securities reaffirmed a buy rating on shares of Motif Bio in a research report on Friday, December 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of GBX 101.50 ($1.40).
Motif Bio (MTFB) opened at GBX 31 ($0.43) on Tuesday. Motif Bio has a 12-month low of GBX 23.50 ($0.32) and a 12-month high of GBX 51.75 ($0.71). The stock has a market cap of $93.75 and a P/E ratio of -119.23.
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.